ISDA

Entry Detail

PDB ID:

5TQ3

Keywords:

Title:

Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Homo sapiens

PDB Version:

Deposition Date:

2016-10-23

Release Date:

2017-01-11

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.69 Å

R-Value Free:

0.27

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase JAK2
Mutations:M1073S, F1076S, I1126V
Chain IDs:A, B
Chain Length:304
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:O60674 Pfam ID:PF07714 EC:2.7.10.2

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
PTR	A	TYR	modified residue

Ligand Molecules

7GZ

Primary Citation

Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.

Jones, P, Storer, R.I, Sabnis, Y.A, Wakenhut, F.M, Whitlock, G.A, England, K.S, Mukaiyama, T, Dehnhardt, C.M, Coe, J.W, Kortum, S.W, Chrencik, J.E, Brown, D.G, Jones, R.M, Murphy, J.R, Yeoh, T, Morgan, P, Kilty, I.Show

J. Med. Chem. 60 767 786 (2017)

PMID: 27983835 DOI: 10.1021/acs.jmedchem.6b01634

Abstact

By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures